These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2908162)

  • 1. Synaptic and non-synaptic striatal dopamine D2 receptors: possible implications in normal and pathological behaviour.
    Korf J; Loopuijt LD
    Acta Morphol Neerl Scand; 1988-1989; 26(2-3):177-90. PubMed ID: 2908162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease.
    Calabresi P; Mercuri NB; Sancesario G; Bernardi G
    Brain; 1993 Apr; 116 ( Pt 2)():433-52. PubMed ID: 8096420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    Costentin J
    Encephale; 1979; 5(2):121-49. PubMed ID: 38958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localization and pharmacology of some dopamine receptor complexes in the striatum and the pituitary gland: synaptic and son-synaptic communication.
    Stoof JC
    Acta Morphol Neerl Scand; 1988-1989; 26(2-3):115-30. PubMed ID: 2855385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
    Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
    Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain neurotransmitters and neuropeptides in Parkinson's disease.
    Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P
    Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal ventral mesencephalic grafts functionally reduce the dopamine D2 receptor supersensitivity in partially dopamine reinnervated host striatum.
    Strömberg I; Kehr J; Andbjer B; Fuxe K
    Exp Neurol; 2000 Jul; 164(1):154-65. PubMed ID: 10877926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intrastriatal injection of thrombin in rat induced a retrograde apoptotic degeneration of nigral dopaminergic neurons through synaptic elimination.
    Herrera AJ; de Pablos RM; Carreño-Müller E; Villarán RF; Venero JL; Tomás-Camardiel M; Cano J; Machado A
    J Neurochem; 2008 May; 105(3):750-62. PubMed ID: 18179476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphetamine depresses excitatory synaptic transmission at prefrontal cortical layer V synapses.
    Mair RD; Kauer JA
    Neuropharmacology; 2007 Jan; 52(1):193-9. PubMed ID: 16895728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action.
    Hertel P
    Synapse; 2006 Dec; 60(7):543-52. PubMed ID: 16952163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disturbances in neurotransmission processes in aging and age-related diseases.
    Ossowska K
    Pol J Pharmacol; 1993; 45(2):109-31. PubMed ID: 8401765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia.
    Lee J; Zhu WM; Stanic D; Finkelstein DI; Horne MH; Henderson J; Lawrence AJ; O'Connor L; Tomas D; Drago J; Horne MK
    Brain; 2008 Jun; 131(Pt 6):1574-87. PubMed ID: 18487277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine and acetylcholine cell density in the neuroleptic responsive (NR) and neuroleptic nonresponsive (NNR) lines of mice.
    Hitzemann R; Qian Y; Hitzemann B
    J Pharmacol Exp Ther; 1993 Jul; 266(1):431-8. PubMed ID: 8101223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT; White FJ
    Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y; Villalba R
    Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism.
    St-Hilaire M; Landry E; Lévesque D; Rouillard C
    Neurobiol Dis; 2005 Nov; 20(2):450-60. PubMed ID: 15896973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical neurotransmission in the parkinsonian brain.
    Rinne UK; Rinne JO; Rinne JK; Laakso K
    Med Biol; 1987; 65(2-3):75-81. PubMed ID: 2821331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.
    Abramsky O; Litvin Y
    Perspect Biol Med; 1978; 22(1):104-14. PubMed ID: 733451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.